DB:DYF1

Stock Analysis Report

Executive Summary

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation.


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Dynavax Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DYF1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-14.3%

DYF1

-8.1%

DE Biotechs

-6.8%

DE Market


1 Year Return

-56.2%

DYF1

2.8%

DE Biotechs

6.5%

DE Market

Return vs Industry: DYF1 underperformed the German Biotechs industry which returned 2.8% over the past year.

Return vs Market: DYF1 underperformed the German Market which returned 6.5% over the past year.


Shareholder returns

DYF1IndustryMarket
7 Day-14.3%-8.1%-6.8%
30 Day-22.5%-9.4%-3.7%
90 Day-21.0%-4.5%-3.6%
1 Year-56.2%-56.2%3.0%2.8%9.8%6.5%
3 Year-40.7%-40.7%31.3%29.9%6.8%-2.6%
5 Year-77.1%-77.1%6.9%4.6%12.5%-2.9%

Price Volatility Vs. Market

How volatile is Dynavax Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Dynavax Technologies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DYF1 (€3.98) is trading below our estimate of fair value (€27.79)

Significantly Below Fair Value: DYF1 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DYF1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: DYF1 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DYF1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DYF1 is overvalued based on its PB Ratio (9.4x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Dynavax Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

50.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DYF1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DYF1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DYF1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DYF1's revenue (36% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: DYF1's revenue (36% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DYF1's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Dynavax Technologies performed over the past 5 years?

-10.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DYF1 is currently unprofitable.

Growing Profit Margin: DYF1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DYF1 is unprofitable, and losses have increased over the past 5 years at a rate of -10.8% per year.

Accelerating Growth: Unable to compare DYF1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DYF1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: DYF1 has a negative Return on Equity (-397.93%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Dynavax Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: DYF1's short term assets ($228.8M) exceed its short term liabilities ($46.3M).

Long Term Liabilities: DYF1's short term assets ($228.8M) exceed its long term liabilities ($215.5M).


Debt to Equity History and Analysis

Debt Level: DYF1's debt to equity ratio (453.6%) is considered high.

Reducing Debt: DYF1's debt to equity ratio has increased from 0.09% to 453.6% over the past 5 years.


Balance Sheet

Inventory Level: DYF1 has a high level of physical assets or inventory.

Debt Coverage by Assets: DYF1's debt is covered by short term assets (assets are 1.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DYF1 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if DYF1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Dynavax Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate DYF1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DYF1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DYF1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DYF1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DYF1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Ryan Spencer 0

0.2yrs

Tenure

0

Mr. Ryan Spencer serves as the Chief Executive Officer & Director of Dynavax Technologies Corp. since December 16, 2019. He had been Co-President and Co-Principal Executive Officer of Dynavax Technologies  ...


Leadership Team

NamePositionTenureCompensationOwnership
David Novack
President & COO0.2yrsUS$1.70m0.15% $502.3k
Dennis Carson
Co-Founder & Member of Scientific Advisory Board1.7yrsUS$196.77k0.0081% $27.6k
Michael Ostrach
CFO, Chief Business Officer & Senior VP4.9yrsUS$3.56m0.18% $622.7k
Robert Janssen
Chief Medical Officer & Senior VP of Clinical Development6.6yrsUS$1.74m0.26% $894.6k
Ryan Spencer
CEO & Director0.2yrsno data0.034% $114.0k
David Johnson
VP & Chief Accounting Officer6yrsno data0.055% $188.1k
Heather Rowe
Vice President of Investor Relations & Corporate Communications1.1yrsno datano data
Steven Gersten
Chief Ethics & Compliance Officer0yrsno datano data
Cecilia Vitug
Vice President of Human Resources13.3yrsno datano data
Jeff Coon
Senior Vice President of Human Resources & Corporate Services1.1yrsno datano data

3.0yrs

Average Tenure

65yo

Average Age

Experienced Management: DYF1's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dennis Carson
Co-Founder & Member of Scientific Advisory Board1.7yrsUS$196.77k0.0081% $27.6k
Ryan Spencer
CEO & Director0.2yrsno data0.034% $114.0k
Peggy Phillips
Independent Director13.5yrsUS$221.77k0.036% $123.5k
Daniel Kisner
Independent Director9.6yrsUS$213.77k0.0018% $6.1k
Arnold Oronsky
Chairman14yrsUS$231.77k0.045% $152.0k
Francis Cano
Independent Director10.3yrsUS$208.77k0.020% $67.6k
Natale Ricciardi
Independent Director6.7yrsUS$201.77kno data
Stanley Plotkin
Member of Scientific Advisory Board1.7yrsUS$20.00kno data
Miriam Merad
Member of Scientific Advisory Board1.7yrsno datano data
Laura Q. Chow
Member of Scientific Advisory Board1.7yrsno datano data

4.2yrs

Average Tenure

72yo

Average Age

Experienced Board: DYF1's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.6%.


Top Shareholders

Company Information

Dynavax Technologies Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dynavax Technologies Corporation
  • Ticker: DYF1
  • Exchange: DB
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$369.845m
  • Listing Market Cap: US$339.962m
  • Shares outstanding: 83.87m
  • Website: https://www.dynavax.com

Number of Employees


Location

  • Dynavax Technologies Corporation
  • 2929 Seventh Street
  • Suite 100
  • Berkeley
  • California
  • 94710
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DVAXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2004
DYF1DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2004
0IDALSE (London Stock Exchange)YesCommon StockGBUSDFeb 2004

Biography

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its product candidates include SD-101, a cancer immunotherapy that is in Phase 2 clinical trials; DV281, an investigational TLR9 agonist, which is in Phase I clinical trial for the treatment of non-small cell lung cancer; and AZD1419, which is in Phase IIa clinical trial to treat asthma. Dynavax Technologies Corporation has a collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/26 21:22
End of Day Share Price2020/02/26 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.